Fr. 135.00

Immunosurveillance, Immunodeficiencies and Lymphoproliferations - Lymphoproliferative Disorders in Congenital and Acquired Immunodeficiencies

Inglese · Tascabile

Spedizione di solito entro 6 a 7 settimane

Descrizione

Ulteriori informazioni

This book covers lymphoproliferative disorders in patients with congenital or acquired immunodeficiencies. Acquired immunodeficiencies are caused by infections with the human immunodeficiency virus or arise following immunosuppressive therapy administered after organ transplantation or to treat connective tissue diseases such as rheumatoid arthritis. It was recently discovered that various diseases or therapeutic modalities that induce a state of immunosuppression may cause virally driven lymphoproliferations. This book summarizes for the first time this group of immunodeficiency-associated lymphoproliferations.

Sommario

Immunosurveillance, Immunodeficiency and Lymphoproliferations.- Clinicopathological Characteristics of Post-Transplant Lymphoproliferative Disorders.- Latrogenic Lymphoproliferative Disorders in Non-Transplantation Settings.- The Role of Kaposi's Sarcoma-Associated Herpesvirus (KSHV/HHV-8) in Lymphoproliferative Diseases.- Dendritic Cells for the Induction of EBV Immunity.- NF-?B Inhibition in EBV-Transformed Lymphoblastoid Cell Lines.- Epstein-Barr Viral Load as a Tool to Diagnose and Monitor Post-Transplant Lymphoproliferative Disease.- The Role of Immunosuppression in Lymphoma.- Indentification of Prognostic Factors in Post-Transplant Lymphoproliferative Disorders.- Methods and Objectives of a Large US Multicenter Case-Control Study of Post-Transplant Lymphoproliferative Disorder in Renal Transplant Patients.- Antiviral Treatment of Epstein-Barr Virus-Associated Lymphoproliferations.- Low-Dose Chemotherapy for Children with Post-Transplant Lymphoproliferative Disease.- Engineered Antibody for Treating Lymphoma.- Treatment of Post-Transplant Lymphomas with Anti-B-Cell Monoclonal Antibodies.- Epstein-Barr Virus (EBV)-Specific Cytotoxic T Lymphocytes for the Prevention and Treatment of EBV-Associated Post-Transplant Lymphomas.- Non-Myeloablative Stem Cell Transplantation for Congenital Immunodeficiencies.- Prognostic Factors in the Treatment of Human Immunodeficiency Virus-Associated Non-Hodgkin's Lymphoma.- Infusional CDE with Rituximab for the Treatment of Human Immunodeficiency Virus-Associated Non-Hodgkin's Lymphoma: Preliminary Results of a Phase I/II Study.

Riassunto

This book covers lymphoproliferative disorders in patients with congenital or acquired immunodeficiencies. Acquired immunodeficiencies are caused by infections with the human immunodeficiency virus or arise following immunosuppressive therapy administered after organ transplantation or to treat connective tissue diseases such as rheumatoid arthritis. It was recently discovered that various diseases or therapeutic modalities that induce a state of immunosuppression may cause virally driven lymphoproliferations. This book summarizes for the first time this group of immunodeficiency-associated lymphoproliferations.

Dettagli sul prodotto

Con la collaborazione di H Oertel (Editore), S H Oertel (Editore), S. H. Oertel (Editore), S.H. Oertel (Editore), Riess (Editore), Riess (Editore), H. Riess (Editore)
Editore Springer, Berlin
 
Lingue Inglese
Formato Tascabile
Pubblicazione 08.03.2013
 
EAN 9783642626760
ISBN 978-3-642-62676-0
Pagine 158
Illustrazioni X, 158 p.
Serie Recent Results in Cancer Research
Recent Results in Cancer Research
Categorie Scienze naturali, medicina, informatica, tecnica > Medicina > Branche non cliniche

Hämatologie, C, Medicine, Hematology, Oncology, Cancer Research, Haematology, Cancer Biology

Recensioni dei clienti

Per questo articolo non c'è ancora nessuna recensione. Scrivi la prima recensione e aiuta gli altri utenti a scegliere.

Scrivi una recensione

Top o flop? Scrivi la tua recensione.

Per i messaggi a CeDe.ch si prega di utilizzare il modulo di contatto.

I campi contrassegnati da * sono obbligatori.

Inviando questo modulo si accetta la nostra dichiarazione protezione dati.